1. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin J,2019
2. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty KT,2012
3. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial;Davies MA,2017
4. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto PA,2016
5. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications;Grossmann KF,2015